Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GUSB | P08236 | 9/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HAT1 | O14929 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.37 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708298 | 0.86 | RAB9A (0.42) | GUSBNR4A2HAT1EP300NHERF1 | |
| SCHEMBL71626 | 0.85 | PKM (0.57) | PKMKDM4EALDH1A1KMT2ANHERF1 | |
| SCHEMBL72295 | 0.82 | PKM (0.54) | PKMKDM4EALDH1A1KMT2ANHERF1 | |
| SCHEMBL14591887 | 0.80 | HAT1 (0.41) | POLBGUSBNR4A2HAT1EP300 | |
| SCHEMBL73880 | 0.75 | MAOB (0.47) | — | |
| SCHEMBL5708317 | 0.75 | SMN1; SMN2 (0.43) | POLBKDM4EALDH1A1KMT2A | |
| SCHEMBL3579447 | 0.74 | ITGB1 (0.56) | NR4A2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL72819 | 0.73 | MAOB (0.45) | — | |
| SCHEMBL72217 | 0.73 | MAPT (0.41) | L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL14254463 | 0.73 | ITGB1 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1698611-A1 | PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | UGT1A4, VPS4B, CYP3A4 | PKM 557/4885POLB 1933/4885GUSB 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.